We are delighted to share with you that the 2nd Pan-Middle East Conference on Thalassaemia & other Haemoglobinopathies was organized by the Thalassaemia International Federation (TIF) was completed with great success between the 11th and the 12th November 2016 in Amman (Jordan) in the context of TIF’s renowned educational program of international calibre.
Organised in collaboration with the Jordanian Thalassemia & Hemophilia Society and Ministry of Health of Jordan, this Conference provided an outstanding opportunity for all involved stakeholders to bridge perspectives from various disciplines and to meet the challenges of improving the health and quality of life of those affected by haemoglobinopathies. This conference constituted a unique forum for sharing knowledge and experiences and for building up new friendships, collaborations, partnerships and networks.
The Conference was marked by the strong presence of the Middle East Regional Office of the World Health Organization (EMRO). The former First Lady of Lebanon and representatives of Highness Sheikha Sheikha Bint Seif Al Nahyan of Abu Dabhi (United Arab Emirates) have also participated.
During the Conference, two parallel programs were held- one for health professionals and one for patients, offering a unique opportunity for approximately 300 participants (health professionals, specialists, researchers, parents and patients), from 36 countries of the region (and beyond) to interact and exchange information regarding the latest research developments in the field of thalassaemia. The conference topics were covered by over 20 expert specialists / scientists of national, regional and international calibre.
The conference also offered a means for patients to voice their concerns and share their claim their rights to access to safe and quality healthcare.
In the context of this Conference, two very important events took place:
- The official launching of TIF’s publications in Arabic, «All About Thalassaemia» and «Sickle Cell Disease».
- The announcement of research results for the new formulation of pharmaceutical drugs for iron chelation which aim to improve the health and quality of life of patients and encourage their compliance for treatment.
As a result of the interactive discussions which took place during the Conference, and taking into account the specificities of this particular region of the world, TIF, in collaboration with individual local patient associations and regional experts in the field, develop a more empowered than the World Health organization and the United Nations. The aim will be decent quality of life of patients and the provision of quality health care to the chronically ill by national health services.
Based on the knowledge and vast experience, thalassemia can be effectively prevented and treated clinically. In fact, today there are many, varied and reasonable grounds for its holistic treatment in the near future. So there is no excuse for any delay on the part of governments and international health organizations for not developing and implementing preventive screening programs and clinical management of thalassemia and haemoglobinopathies.